Status:
WITHDRAWN
Expression Profile of ERK5 and PKM2 Kinases in Neuroinflammatory Diseases.
Lead Sponsor:
Centre Hospitalier Régional d'Orléans
Collaborating Sponsors:
Immunologie et Neurogénétique Expérimentales et Moléculaires (INEM)
Conditions:
Sclerosis, Multiple
Guillain-Barre Syndrome
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
Demyelinating diseases represent a broad spectrum of disorders and are induced by excessive inflammation most often triggered by an autoimmune mechanism. Some of these pathologies are chronic and affe...
Detailed Description
The study of the expression of ERK5 and PKM2 kinases in patients followed for RR MS or GBS, at the beginning of the pathology, will be evaluate. The usual diagnostic workup for MS and GBS will be per...
Eligibility Criteria
Inclusion
- Man and Woman
- 18 to 80 years old
- Clinical signs that suggest MS or GBS within a month of onset symptom
Exclusion
- Patient treated with immunosuppressive therapy, immunomodulator, or corticosteroids in chronic treatment
- Patient treated with corticosteroids in the past month
- without social security
- HIV positive serology
- dementia
- pregnant or breastfeeding woman
- previous participation in the study
- under judicial protection
- non-cooperating patient
Key Trial Info
Start Date :
January 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04674163
Start Date
January 1 2023
End Date
January 1 2023
Last Update
January 23 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.